drugset / Trial / NCT03981952

Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine

NCT03981952 ↗

Phase 1 Completed 96 enrolled University of Maryland, Baltimore
RandomizedSequentialQuadruple-blindPrevention

Summary

This is a randomized, placebo-controlled dose-escalation study. The main purpose of this research is to test the safety and measure the immune response of the trivalent vaccine against invasive Salmonella disease. The vaccine will be tested over a range of doses.

Timeline

Start
2019-10-28
Primary completion
2021-05-07
Completion
2021-05-07

Outcome

Met primary endpoint

paper TSCV was safe and well tolerated, meeting the prespecified safety endpoints PMID 41062830 ↗

paper For each of the three polysaccharides, immune responses, as demonstrated by ≥4-fold increases over baseline, were observed among all (100%) vaccinees PMID 41062830 ↗

paper meeting the prespecified immunogenicity endpoints PMID 41062830 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Trivalent Salmonella Conjugate Vaccine Vaccine 6.25 ug Intramuscular
Subject Trivalent Salmonella Conjugate Vaccine Vaccine 12 ug Intramuscular
Subject Trivalent Salmonella Conjugate Vaccine Vaccine 25 ug Intramuscular

Indications

No indication recorded.